肉毒毒素辅助Rives修补避免中线巨大疝组件分离
前瞻性比较研究纳入80例中线巨大切口疝(横径11-17 cm)患者,术前肉毒毒素组40例后续行开放Rives修补,对照组40例行开放组件分离。肉毒毒素组全部实现筋膜闭合,无给药并发症,手术部位并发症(尤其皮肤坏死)显著少于组件分离组;随访中疝复发仅见于组件分离组。
要点
- 术前肉毒毒素可使横径11-17 cm中线巨大切口疝降期至Rives修补。
- 肉毒毒素组全部实现筋膜闭合,给药期间无并发症。
- 组件分离组皮肤坏死更多,随访复发仅见于该组。
核心结论
- 术前肉毒毒素可使中线巨大切口疝(横径11-17 cm)成功降期至Rives修补,并减少前组件分离相关弊端。
研究设计与样本
- 2016年3月至2019年6月单中心前瞻性比较研究,连续纳入80例择期修补的中线巨大切口疝(横径11-17 cm)患者。
- 肉毒毒素组40例术前给药后行开放Rives修补,组件分离组40例同期行开放组件分离。
主要发现
- 所有疝均归为W3,平均横向缺损直径14.9 cm(11.8-16.5),平均纵向缺损直径24 cm(11-28)。
- 肉毒毒素组全部实现筋膜完全闭合,给药期间无并发症。
- 术后中位随访19.6个月(范围11-35),共报告2例疝复发(8.9%),均位于组件分离组。
临床怎么用
- 对横径11-17 cm的中线巨大切口疝,可考虑术前应用肉毒毒素降期后行Rives修补,以降低组件分离相关并发症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The goal of our study was to compare results in patients with large midline incisional hernia using modified anterior component separation versus preoperative botulinum toxin and following Rives repair, with a focus on surgical site occurrences, possibility of fascial closure, duration of hospital stay, and hernia recurrence rate. METHODS: From to March 2016 to June 2019, a prospective comparative study was performed in 80 consecutive patients with large midline incisional hernias and hernia transverse diameters between 11 and 17 cm under elective hernia repair at our tertiary center. Two groups were analyzed prospectively: 40 patients with preoperative botulinum toxin administration and following open Rives repair (botulinum toxin group) were compared with 40 patients who underwent open component separation during that period (component separation group). RESULTS: All large midline incisional hernias were classified W3, with mean transverse and longitudinal defect diameters of 14.9 cm (11.8-16.5) and 24 cm (11-28), respectively. Complete fascial closure was possible in all patients in the preoperative botulinum toxin group. No complications occurred during the administration of preoperative botulinum toxin, but surgical site complications were most frequent in the component separation group, especially skin necrosis (12.5%, P = .020). At a median of 19.6 months (range, 11-35) of postoperative follow-up, 2 cases of hernia recurrence (8.9%) were reported, all of them in the component separation group. CONCLUSION: Botulinum toxin allows getting a successful downstaging from surgical repair to Rives technique in patients with large midline incisional hernia, especially with hernia transverse diameters between 11 and 17 cm. These results contribute to minimize disadvantages associated to the anterior component separation.
引用
- Bueno-Lledó J, Martinez-Hoed J, Torregrosa-Gallud A, et al. Botulinum toxin to avoid component separation in midline large hernias. Surgery. 2020. PMID: 32576404. doi:10.1016/j.surg.2020.04.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。